期刊
CANCER LETTERS
卷 300, 期 1, 页码 48-56出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.09.005
关键词
Multi drug resistance (MDR); P-glycoprotein (P gp); PKD2; Paclitaxel
类别
Multi-drug resistance (MDR) represents a major obstacle for chemotherapeutic treatment of a wide variety of human cancers Increased expression of drug efflux pumps such as the P-glycoprotein (P-gp) have been linked to development of MDR. Herein we have identified protein kinase D isoform 2 (PKD2) as an Important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines PKD2 was expressed with the highest phosphorylated activation status in the MDA-MB-231 cell line MDA-MB-231 cells were also found to exhibit the highest level of resistance to an array of chemotherapeutic drugs To further characterize the relationship between PKD2 activation and MDR, we next focused on the effects of the chemotherapeutic agent paclitaxel in MDA-MB-231 cells Treatment with paclitaxel was shown to induce both PKD2 phosphorylation and P-gp expression in a time-dependent manner Importantly shRNA-mediated knockdown of PKD2 in MDA-MB-231 cells resulted in a significant decrease in resistance to paclitaxel evident as significant decreases in both the IC50 value and the resistance index (RI) Concurrent with the decrease in drug resistance paclitaxel-induced expression of P-gp was also significantly reduced in PKD knockdown cells These results indicate that PKD2 is required for paclitaxel-induced MDR and expression of P-gp Therefore modulation of PKD2 activity represents an attractive therapeutic strategy for Improvement of the clinical effectiveness of chemotherapy (c) 2010 Elsevier Ireland Ltd All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据